Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2005

View Archived Issues

Infliximab shows promise in the treatment of refractory PUK

Memory Pharmaceuticals and Amgen sign agreement on PDE10 inhibitors

Norwood Immunology signs agreement for phase II melanoma vaccine trial

Companies advance various approaches to avian flu

Organizations report discovery of agents for heart failure, arrhythmia, etc.

Repligen in expanded uridine agreement for bipolar disorder

The Vaccine Company secures funding for phase III AML study of PR1 vaccine

Novel treatment options for hepatic disorders described in recent patent literature

Syntonix and Boehringer Ingelheim to optimize therapeutic peptides for inhalation

Lilly to support study of Corlux to mitigate olanzapine-associated weight gain

Method to predict/detect age-related macular degeneration reported by the University of Iowa

Oxycyte produces positive results in preclinical traumatic brain injury study

Hyzaar 100-12.5 mg now available

BCY LifeSciences signs letter of intent for business combination with Pipex

Phase II study of Gabapentin GR completes enrollment

Recombinant osteoprotegerin shows potential in juvenile Paget's disease

New mGluR1 antagonist shows promise as an analgesic

Abbott profiles its new highly selective dopamine D4 receptor agonist

Blocking P-glycoprotein increases Abeta accumulation

Bevacizumab improves visual acuity of patients with neovascular AMD

Clinical evidence supports the use of Evizon in wet AMD

Trastuzumab significantly improves disease-free survival in early stage HER2-positive breast cancer

Lurasidone effective in acute exacerbation of schizophrenia

Cognitive parameters improved with ispronicline in age-associated memory impairment

CV Therapeutics withdraws ranolazine MAA with plans to resubmit

Japanese approval for Avelox

Tostrex launched in Sweden